Curr Diab Rep (2017) 17: 124 https://doi.org/10.1007/s11892-017-0954-4 MACROVASCULAR COMPLICATIONS IN DIABETES (VR ARODA AND A GETANEH, SECTION EDITORS) The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? 1 1,2 Laurentiu M. Pop & Ildiko Lingvay Published online: 23 October 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Sulphonylurea Cardiovascular disease . . . Purpose of Review Sulfonylureas (SUs) are one of the most Cardiovascular safety Type 2 diabetes Healthcare cost commonly used glucose-lowering agents worldwide. While Ischemic preconditioning their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings With no dedicated cardiovascular studies Introduction to definitively answer this question, observational studies and meta-analyses abound and have reported divergent The safety profile of pharmacologic agents plays an important results, fueling the controversy. Studies that compared role in defining their risk-benefit ratio, especially when these SUs to metformin or newer agents, like GLP-1 agonists agents are used to treat chronic morbidities which require life- and SGLT2 inhibitors, suggest a difference in cardiovas- long management, like type 2 diabetes mellitus (T2DM). The cular events, yet this is likely the result of beneficial treatment armamentarium for T2DM has expanded impres- effects of the latter.
Current Diabetes Reports – Springer Journals
Published: Oct 23, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud